Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial
PaperCitations, authors & open-access status
Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 143 citations, 2024 year and bronze oa status.
143
Citations
2024
Year
bronze
OA Status